ATRYS HEALTH, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.88 EUR | -0.35% |
|
-2.37% | -21.53% |
| Mar. 26 | Atrys Health, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Atrys Health, S.A. announced that it has received ?13.3 million in funding | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. It has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The Company has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.88
EUR
Average target price
6.61
EUR
Spread / Average Target
+129.51%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.53% | 233M | |
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +11.62% | 29.4B | |
| -12.71% | 16.73B | |
| -3.06% | 16.36B | |
| -2.63% | 14.92B | |
| -31.75% | 11.77B | |
| -1.42% | 11.72B | |
| +27.44% | 11.71B |
- Stock Market
- Equities
- ATRY Stock
- News Atrys Health, S.A.
- Atrys Health Buys Spanish Cancer Care Provider Initia Oncología
